We are monitoring the impact of COVID-19 on APAC Infectious Disease Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date April, 2021
ID: 1248
Share on
Share on

Asia Pacific Infectious Disease Therapeutics Market Research Report – Segmented By Mode Of Treatment, Target Organism, Infection Type, Distribution Channels and Country (India, China, Japan, South Korea, Australia, New Zealand, Thailand, Malaysia, Vietnam, Philippines, Indonesia, Singapore and Rest of APAC) - Industry Analysis, Size, Share, Trends & Growth Forecast (2021 to 2026)

Pulished: April, 2021
ID: 1248
Pages: 132

APAC Infectious Disease Therapeutics Market Size (2021 to 2026)

The size of the Asia-Pacific Infectious Disease Therapeutics Market was worth USD 18.38 Billion in 2021. It is further estimated to grow and be worth USD 28.63 Billion by the end of 2026, growing at a CAGR of 9.27% between 2021 to 2026. Asia-Pacific is expected to account for the second-largest share in the market due to the increasing pool of patients and government funding.

Infectious diseases such as HIV, malaria, tuberculosis, hepatitis A, B, C, and influenza are among the most severe threats to public health in the Asia Pacific. In the Asia-Pacific, infectious diseases are the leading cause of death. According to the World Health Organization (WHO), infectious diseases are responsible for 16% of worldwide deaths.

Y-O-Y rise in the prevalence of infectious diseases, technological developments, and more government financing and investments are a few of the key factors accelerating the growth rate of the infectious disease therapeutics market in the APAC region. In the worldwide infectious diseases treatments market, Asia Pacific is predicted to rise at the fastest growth rate during the forecast period. The enormous pool of patients and increased government financing are two significant driving reasons for emerging countries' infectious diseases treatments industry. In addition, growing usage of infectious diseases therapeutics, increased use of direct-acting antivirals, increasing elderly population, and rising healthcare expenditure are key drivers driving the growth of the Asia-Pacific infectious diseases therapeutics market.

More significant investments to enhance the penetration rate of infectious illness treatments, higher initiatives to raise knowledge about treatments and diagnosis, and increased clinical trial studies for developing new pharmaceuticals are further predicted to move this market forward during the forecast period.

However, factors that are expected to hinder the market growth of infectious disease therapies in the Asia Pacific, including a lack of advanced healthcare facilities in underdeveloped countries, which is expected to have a downward trend in the market growth over the projected timeframe. In addition, the high cost of hospitalization, restrictions on senior people accessing modern therapies, a lack of public understanding of new treatment methods, and social isolation in public gatherings are all barriers to market growth.

This research report on the Asia Pacific infectious disease therapeutics market has been segmented & sub-segmented into the following categories:

By Mode of Treatment:

  • Drugs     
  • Vaccines    

By Target Organism:

  • Antibacterial      
  • Antifungal
  • Antiviral  
  • Antiparasite      
  • others     

By Infection type: 

  • Bacterial  
  • Viral      
  • Fungal    
  • Parasitic  
  • Others    

By Distribution Channels: 

  • Hospitals  
  • Clinics     
  • Others

By Country:

  • India
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Thailand
  • Malaysia
  • Vietnam
  • Philippines
  • Indonesia
  • Singapore
  • Rest of APAC

Geographically, the Asia-Pacific region is one of the most rapidly developing. Infectious disease drugs are expected to be in high demand in the region due to the increased prevalence of such conditions and a favorable reimbursement environment. Furthermore, China and India have a significant number of producers and an increasing number of clinical trials for the development of novel therapeutic drugs, which are expected to add to the region's large market.  The growing prevalence of infectious disease treatment and diagnostics and increased funding initiatives to assist the development of innovative drugs are expected to propel this business forward.

The high prevalence of HIV, malaria, tuberculosis and other infections in China and India, the rising incidence of these diseases, and rising expenditure on infectious disease prevention and diagnostics are expected to drive the regional market's growth. Moreover, throughout the forecast period, governments of various countries are expected to increase their attention on infection prevention and generate funds to support the adoption of therapies for infectious diseases, driving the market even further.

KEY MARKET PLAYERS:

Companies playing a significant role in the APAC Infectious disease Therapeutics Market profiled in this report are F. Hoffmann-La Roche, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, Merck & Co, Pfizer, Achillion Pharmaceuticals, Novartis, AbbVie, Astellas Pharma, AstraZeneca, Auritec Pharmaceuticals, Bayer, Bristol-Myers Squibb, Chimerix Pharmaceuticals, Cubist, Eli Lilly, Isis Pharmaceuticals, Mitsubishi Tanabe Pharma, pSivida and Sanofi.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                             

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 Mode of Treatment                

                                5.1.1 Introduction           

                                5.1.2 Drugs        

                                                5.1.2.1 Oral Administration

                                                5.1.2.2 Topical

                                                5.1.2.3 Injections

                                                5.1.2.4 Others

                                5.1.3 Vaccines  

                                5.1.4 Y-o-Y Growth Analysis, By Mode of treatment         

                                5.1.5 Market Attractiveness Analysis, By Mode of treatment        

                                5.1.6 Market Share Analysis, By Mode of treatment         

                5.2 Target Organism                      

                                5.2.1 Introduction           

                                5.2.2 Antibacterial          

                                5.2.3 Antifungal

                                5.2.4 Antiviral   

                                5.2.5 Antiparasite           

                                5.2.6 others       

                                5.2.7 Y-o-Y Growth Analysis, By Target Organism               

                                5.2.8 Market Attractiveness Analysis, By Target Organism             

                                5.2.9 Market Share Analysis, By Target Organism              

                5.3 Infection type                           

                                5.3.1 Introduction           

                                5.3.2 Bacterial   

                                5.3.3 Viral           

                                5.3.4 Fungal       

                                5.3.5 parasitic   

                                5.3.6 others       

                                5.3.7 Y-o-Y Growth Analysis, By Infection type    

                                5.3.8 Market Attractiveness Analysis, By Infection type  

                                5.3.9 Market Share Analysis, By Infection Type   

                5.4 Distribution Channels                            

                                5.4.1 Hospitals  

                                5.4.2 Clinics        

                                5.4.3 Others      

                                5.4.4 Y-o-Y Growth Analysis, By Distribution Channels     

                                5.4.5 Market Attractiveness Analysis, By Distribution Channels   

                                5.4.6 Market Share Analysis, By Distribution Channels    

6. Geographical Analysis                                              

                6.1 Introduction                              

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Mode of Treatment

                                                6.1.3.3 By Target organism

                                                6.1.3.4 By Infection Type

                                                6.1.3.5 By Distribution Channels

                                6.1.4 Market Attractiveness Analysis      

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Mode of Treatment

                                                6.1.4.3 By Target organism

                                                6.1.4.4 By Infection Type

                                                6.1.4.5 By Distribution Channels

                                6.1.5 Market Share Analysis        

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Mode of Treatment

                                                6.1.5.3 By Target organism

                                                6.1.5.4 By Infection Type

                                                6.1.5.5 By Distribution Channels

                6.2 China                            

                6.3 India                              

                6.4 Japan                            

                6.5 South Korea               

                6.6 Australia                      

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental      

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services

                                7.2.5 Competitive Rivalry within the Industry      

8.Market Leaders' Analysis                                          

                8.1 F. Hoffmann-La Roche                           

                                8.1.1 Overview

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Gilead Sciences                         

                8.3 GlaxoSmithKline                      

                8.4 Johnson & Johnson                 

                8.5 Merck & Co                

                8.6 Pfizer                            

                8.7 Achillion Pharmaceuticals                    

                8.8 Novartis                       

                8.9 Abbvie                         

                8.10 Astellas Pharma                     

                8.11 AstraZeneca                            

                8.12 Auritec Pharmaceuticals                     

                8.13 Bayer                          

                8.14 Bristol-Myers Squibb                           

                8.15 Chimerix Pharmaceuticals                 

                8.16 Cubist                         

                8.17 Eli Lilly                        

                8.18 Isis Pharmaceuticals                             

                8.19 pSivida                       

                8.20 Sanofi                         

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                        

                9.3 Agreements, collaborations and Joint Ventures                          

                9.4 New Product Launches                          

10.Market Outlook and Investment Opportunities                                           

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Asia-Pacific Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  2. Asia-Pacific Drugs Market, By Region, From 2021 to 2026 (USD Billion)
  3. Asia-Pacific vaccines Market, By Region, From 2021 to 2026 (USD Billion)
  4. Asia-Pacific Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  5. Asia-Pacific Antibacterial Market, By Region, From 2021 to 2026 (USD Billion)
  6. Asia-Pacific Antifungal Market, By Region, From 2021 to 2026 (USD Billion)
  7. Asia-Pacific Antiviral Market, By Region, From 2021 to 2026 (USD Billion)
  8. Asia-Pacific Antiparasite Market, By Region, From 2021 to 2026 (USD Billion)
  9. Asia-Pacific Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  10. Asia-Pacific Bacterial Market, By Region, From 2021 to 2026 (USD Billion)
  11. Asia-Pacific Viral Market, By Region, From 2021 to 2026 (USD Billion)
  12. Asia-Pacific Fungal Market, By Region, From 2021 to 2026 (USD Billion)
  13. Asia-Pacific Parasitic Market, By Region, From 2021 to 2026 (USD Billion)
  14. Asia-Pacific Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  15. Asia-Pacific Hospitals Market, By Region, From 2021 to 2026 (USD Billion)
  16. Asia-Pacific Clinics Market, By Region, From 2021 to 2026 (USD Billion)
  17. Japan Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  18. Japan Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  19. Japan Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  20. Japan Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  21. China Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  22. China Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  23. China Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  24. China Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  25. India Infectious Disease Therapeutics Market, By Mode of treatment, From 2021 to 2026 (USD Billion)
  26. India Infectious Disease Therapeutics Market, By Target Organism, From 2021 to 2026 (USD Billion)
  27. India Infectious Disease Therapeutics Market, By Infection Type, From 2021 to 2026 (USD Billion)
  28. India Infectious Disease Therapeutics Market, By Distribution Channels, From 2021 to 2026 (USD Billion)
  29. Asia-Pacific Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  30. Asia-Pacific Oral Administration Market, By Region, From 2021 to 2026 (USD Billion)
  31. Asia-Pacific Topical Market, By Region, From 2021 to 2026 (USD Billion)
  32. Asia-Pacific Injections Market, By Region, From 2021 to 2026 (USD Billion)
  33. Japan Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  34. China Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)
  35. India Infectious disease Therapeutics Market, By Drugs, From 2021 to 2026 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample